Signal transduction

Bayer Submits Regulatory Applications for Oncology Treatment Investigational Combination of Aliqopa® (copanlisib) and rituximab in the U.S. and EU

Retrieved on: 
Monday, June 21, 2021
Biotechnology, FDA, Other Health, Health, General Health, Pharmaceutical, Oncology, Other Science, Research, Science, Clinical trials, Branches of biology, Biology, Oncology, Cell signaling, Programmed cell death, Phosphoinositide 3-kinase, Signal transduction, Kinase, Apoptosis, Phosphoinositide 3-kinase inhibitor, PI3K/AKT/mTOR pathway, Aliqopa® (copanlisib) Injection, non-Hodgkin’s Lymphoma, Oncology at Bayer, Bayer, ALIQOPA® (COPANLISIB) INJECTION, NON-HODGKIN’S LYMPHOMA, ONCOLOGY AT BAYER, BAYER

In the EU, Bayer has filed for the treatment of relapsed marginal zone lymphoma (MZL), a subtype of iNHL, and the filing has been accepted.

Key Points: 
  • In the EU, Bayer has filed for the treatment of relapsed marginal zone lymphoma (MZL), a subtype of iNHL, and the filing has been accepted.
  • Aliqopa is an inhibitor of phosphatidylinositol-3-kinase (PI3K) with inhibitory activity predominantly against PI3K- and PI3K- isoforms expressed in malignant B cells.
  • Aliqopa has been shown to induce tumor cell death by apoptosis and inhibition of proliferation of primary malignant B cell lines.
  • The clinical development program for Aliqopa also includes the Phase III study CHRONOS-4, evaluating Aliqopa in combination with standard immunochemotherapy in relapsed iNHL.

eFFECTOR Therapeutics to Present at JMP Securities 2021 Life Sciences Conference

Retrieved on: 
Monday, June 14, 2021
Biology, Signal transduction, MTOR, Effector, Protein kinases

eFFECTOR is a clinical stage biopharmaceutical company focused on pioneering the development of a new class of oncology drugs referred to as selective translation regulator inhibitors.

Key Points: 
  • eFFECTOR is a clinical stage biopharmaceutical company focused on pioneering the development of a new class of oncology drugs referred to as selective translation regulator inhibitors.
  • eFFECTORs STRI product candidates target the eIF4F complex and its activating kinase, mitogen-activated protein kinase 1/2 (MNK 1/2).
  • On May 26, 2021, eFFECTOR entered into the Merger Agreement with LWAC, a special purpose acquisition company, and Merger Sub, a wholly owned subsidiary of LWAC.
  • Neither LWAC nor eFFECTOR gives any assurance that either LWAC or eFFECTOR or the combined company will achieve its expectations.

TG Therapeutics Announces Data from a Phase 1 Study Evaluating TG-1701 as a Monotherapy and as a Triple Combination with Ublituximab and UKONIQ® at the 2021 European Hematology Association Virtual Congress

Retrieved on: 
Friday, June 11, 2021
Protein kinases, Signal transduction, Ck1, Casein kinase 1, Phosphoinositide 3-kinase, Kinase, PI3

Data from this trial were made available on demand this morning during the 3032 European Hematology Association (EHA) Virtual Congress.

Key Points: 
  • Data from this trial were made available on demand this morning during the 3032 European Hematology Association (EHA) Virtual Congress.
  • UKONIQ is a registered trademark of TG Therapeutics, Inc.
    UKONIQ is the first and onlyoral inhibitor of phosphoinositide 3 kinase (PI3K) delta and casein kinase 1(CK1) epsilon.
  • CK1-epsilonis a regulator of oncoprotein translation and has been implicated in the pathogenesis of cancer cells, including lymphoid malignancies.
  • Monitor for any new or worsening signs and symptoms of infection, including suspected PJP or CMV, during treatment with UKONIQ.

Aadi Bioscience Presents Emerging Data for FYARRO™ in Patients with Solid Tumors Harboring TSC1 or TSC2 Inactivating Alterations from a Multi-Institution Expanded Access Program at ASCO 2021

Retrieved on: 
Friday, June 4, 2021
Branches of biology, Signal transduction, Biology, mTOR inhibitors, Oncology, MTOR, CBR96-doxorubicin immunoconjugate

Patients had a median of 3.5 lines of prior therapy and 6 of 8 patients were mTOR inhibitor-nave.

Key Points: 
  • Patients had a median of 3.5 lines of prior therapy and 6 of 8 patients were mTOR inhibitor-nave.
  • Five of 8 patients continued on treatment as of the data cutoff and 3 of 8 patients discontinued.
  • Of the 8 patients treated, 7 patients were evaluable for response analysis and 1 patient progressed before the first scan.
  • Dr. Neil Desai, founder and chief executive officer of Aadi, stated, "We are pleased to have provided FYARRO to patients through our expanded access program.

TG Therapeutics Announces Data from a Phase 1 Study Evaluating TG-1701 as a Monotherapy and as a Triple Combination with Ublituximab and UKONIQ® at the 2021 American Society of Clinical Oncology Annual Meeting

Retrieved on: 
Friday, June 4, 2021
Protein kinases, Signal transduction, Casein kinase 1, Phosphoinositide 3-kinase, Ck1, PI3

Data from this trial were made available on demand this morning during the American Societyof Clinical Oncology (ASCO) Annual Meeting.

Key Points: 
  • Data from this trial were made available on demand this morning during the American Societyof Clinical Oncology (ASCO) Annual Meeting.
  • TG-1701 monotherapy was well tolerated and the maximum tolerated dose was not reached up to 400 mg QD.
  • TG Therapeuticsis a fully-integrated, commercial stage biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.
  • UKONIQ is a registered trademark of TG Therapeutics, Inc.
    UKONIQ is the first and onlyoral inhibitor of phosphoinositide 3 kinase (PI3K) delta and casein kinase 1(CK1) epsilon.

Yingli Pharma Announces presentations on the Phase 1 trials of linperlisib, a PI3Kδ selective inhibitor, and YL-13027, an oral TGFβR1 inhibitor, at the American Society for Clinical Oncology 2021 Annual Meeting

Retrieved on: 
Friday, June 4, 2021
Branches of biology, Signal transduction, Clinical medicine, Medicine, Oncology, Drug discovery, Phosphoinositide 3-kinase inhibitor, Phosphoinositide 3-kinase, MTOR, Antineoplastic drugs, Quinolines, Dactolisib

Globally, there are no PI3K inhibitors that have been approved for the treatment of T cell lymphomas.

Key Points: 
  • Globally, there are no PI3K inhibitors that have been approved for the treatment of T cell lymphomas.
  • Another clinical study of linperlisib was also presented at ASCO entitled "A phase Ib study of the PI3K inhibitor linperlisib in patients with advanced solid tumors".
  • "YL-13027 has demonstrated to be a safe and tolerable oral agent that is highly selective for TGFR1 over TGFR2.
  • Yingli Pharma is developing best-in-class and first-in-class oral investigational agents for the treatment of cancer, metabolic and autoimmune diseases.

Tectonic Therapeutic Appoints Peter McNamara, PhD Senior Vice President, Head of Research

Retrieved on: 
Thursday, May 27, 2021
Biotechnology, Pharmaceutical, Health, Clinical trials, Branches of biology, Life sciences, Biology, G protein-coupled receptors, Molecular biology, Signal transduction, Biopharmaceutical

Tectonic Therapeutic , a pre-clinical stage biotechnology company transforming the discovery of novel G-protein-coupled receptors (GPCR)-targeted therapies, today announced that Peter McNamara, PhD has been appointed Senior Vice President, Head of Research.

Key Points: 
  • Tectonic Therapeutic , a pre-clinical stage biotechnology company transforming the discovery of novel G-protein-coupled receptors (GPCR)-targeted therapies, today announced that Peter McNamara, PhD has been appointed Senior Vice President, Head of Research.
  • We welcome Peter as a key member of our leadership team at Tectonic.
  • Tectonic has the technology and the experienced team to expand and accelerate the development of GPCR-targeted therapies with biologics, said Dr. McNamara.
  • The GEODe platform that Tectonic has developed is incredibly exciting and can be utilized to develop drugs that improve patient care across a number of therapeutic areas.

BioTheryX Announces $92M Series E Financing to Accelerate Development of Targeted Protein Degradation Pipeline and Technology Platform in Oncology

Retrieved on: 
Thursday, May 20, 2021
Branches of biology, Biology, Life sciences, Biotechnology, Medicinal chemistry, Molecular glue, Kinase, Signal transduction, Cell biology, Proteins

"\nBioTheryX is a clinical-stage biopharmaceutical company focused on restoring protein homeostasis, including protein degradation and modulation, and multi-kinase inhibition to develop treatments intended to extend and improve the quality-of-life of patients with cancer and other diseases.

Key Points: 
  • "\nBioTheryX is a clinical-stage biopharmaceutical company focused on restoring protein homeostasis, including protein degradation and modulation, and multi-kinase inhibition to develop treatments intended to extend and improve the quality-of-life of patients with cancer and other diseases.
  • Our principal technology platform centers on targeted protein degradation, PHM \'molecular glues\', that enable the design of small molecules to regulate protein equilibrium.
  • This technology is designed to utilize the body\'s own protein disposal system to selectively degrade and remove disease-causing proteins.
  • For more information, please visit www.biotheryx.com and engage with us on LinkedIn.\nView original content to download multimedia: http://www.prnewswire.com/news-releases/biotheryx-announces-92m-series-e...\n'

Entera Bio Reports First Quarter 2021 Financial Results and Provides Clinical Updates

Retrieved on: 
Thursday, May 20, 2021
Calcium, Calcium in biology, Signal transduction, Entera, Chemistry, Natural sciences, Physical sciences

Treatment with EB612 resulted in a statistically significant decrease in supplemental calcium usage, maintenance of serum albumin-adjusted calcium, and reduction of serum phosphate.

Key Points: 
  • Treatment with EB612 resulted in a statistically significant decrease in supplemental calcium usage, maintenance of serum albumin-adjusted calcium, and reduction of serum phosphate.
  • Despite the challenges of COVID, I am grateful to the patients, investigators and team\xe2\x80\x99s focus to successfully executing the study.
  • Entera\xe2\x80\x99s operating loss was $2.4 million for the quarter ended March 31, 2021, compared to $2.9 million for the quarter ended March 31, 2020.\nResearch and development expenses were $1.2 million for the quarter ended March 31, 2021, compared to $1.6 million for the quarter ended March 31, 2020.
  • Entera cautions investors not to rely too heavily on the forward-looking statements Entera makes or that are made on its behalf.

Scholar Rock to Present Trials in Progress Poster for SRK-181 DRAGON Phase 1 Clinical Trial at the American Society of Clinical Oncology Annual Meeting

Retrieved on: 
Wednesday, May 19, 2021
Oncology, FDA, Health, Clinical trials, Pharmaceutical, Biotechnology, Endoglin, Signal transduction, SRK-181, Scholar Rock, SRK-181, SCHOLAR ROCK

TGF\xce\xb21 is the predominant TGF\xce\xb2 isoform expressed in many human tumor types.

Key Points: 
  • TGF\xce\xb21 is the predominant TGF\xce\xb2 isoform expressed in many human tumor types.
  • The DRAGON Phase 1 proof-of-concept clinical trial (NCT04291079) in patients with locally advanced or metastatic solid tumors is ongoing.
  • Scholar Rock believes its focus on biologically validated growth factors may facilitate a more efficient development path.
  • Any forward-looking statements represent Scholar Rock\xe2\x80\x99s views only as of today and should not be relied upon as representing its views as of any subsequent date.